tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2024 Dec 31;20(1):2351675.
doi: 10.1080/21645515.2024.2351675. Epub 2024 Jun 4. The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses
David Fisman[SUP] 1 [/SUP], Norberto Giglio[SUP] 2 [/SUP], Myron J Levin[SUP] 3 [/SUP], Van Hung Nguyen[SUP] 4 [/SUP], Stephen I Pelton[SUP] 5 [/SUP], Maarten Postma[SUP] 6 7 8 9 [/SUP], Jesús Ruiz-Aragón[SUP] 10 [/SUP], Analia Urueña[SUP] 11 [/SUP], Joaquin F Mould-Quevedo[SUP] 12 [/SUP]
Affiliations
Seasonal influenza significantly affects both health and economic costs in children and adults. This narrative review summarizes published cost-effectiveness analyses (CEAs) of cell-based influenza vaccines in children and adults <65 years of age, critically assesses the assumptions and approaches used in these analyses, and considers the role of cell-based influenza vaccines for children and adults. CEAs from multiple countries demonstrated the cost-effectiveness of cell-based quadrivalent influenza vaccines (QIVc) compared with egg-based trivalent/quadrivalent influenza vaccines (TIVe/QIVe). CEA findings were consistent across models relying on different relative vaccine effectiveness (rVE) estimate inputs, with the rVE of QIVc versus QIVe ranging from 8.1% to 36.2% in favor of QIVc. Across multiple scenarios and types of analyses, QIVc was consistently cost-effective compared with QIVe, including in children and adults across different regions of the world.
Keywords: Influenza; cell-based influenza vaccine; cost-effectiveness analysis.
. 2024 Dec 31;20(1):2351675.
doi: 10.1080/21645515.2024.2351675. Epub 2024 Jun 4. The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses
David Fisman[SUP] 1 [/SUP], Norberto Giglio[SUP] 2 [/SUP], Myron J Levin[SUP] 3 [/SUP], Van Hung Nguyen[SUP] 4 [/SUP], Stephen I Pelton[SUP] 5 [/SUP], Maarten Postma[SUP] 6 7 8 9 [/SUP], Jesús Ruiz-Aragón[SUP] 10 [/SUP], Analia Urueña[SUP] 11 [/SUP], Joaquin F Mould-Quevedo[SUP] 12 [/SUP]
Affiliations
- PMID: 38835218
- PMCID: PMC11155702
- DOI: 10.1080/21645515.2024.2351675
Seasonal influenza significantly affects both health and economic costs in children and adults. This narrative review summarizes published cost-effectiveness analyses (CEAs) of cell-based influenza vaccines in children and adults <65 years of age, critically assesses the assumptions and approaches used in these analyses, and considers the role of cell-based influenza vaccines for children and adults. CEAs from multiple countries demonstrated the cost-effectiveness of cell-based quadrivalent influenza vaccines (QIVc) compared with egg-based trivalent/quadrivalent influenza vaccines (TIVe/QIVe). CEA findings were consistent across models relying on different relative vaccine effectiveness (rVE) estimate inputs, with the rVE of QIVc versus QIVe ranging from 8.1% to 36.2% in favor of QIVc. Across multiple scenarios and types of analyses, QIVc was consistently cost-effective compared with QIVe, including in children and adults across different regions of the world.
Keywords: Influenza; cell-based influenza vaccine; cost-effectiveness analysis.